Healthcare Market Research Reports & Industry Analysis

Healthcare refers to the field associated with maintaining or restoring patients’ health. These days’ Healthcare Industry falls into a lashing of discrete sub-sectors, and ancillary goods and services. Ranging from therapeutic equipment to medicinal drugs, medical tourism to sickness insurance, the Healthcare Market has been one of the most swiftly expanding sectors within the globe’s economic system.

Global Healthcare spending contributes close to 10% to the whole world’s GDP, though it varies noticeably with geography. Thus, the Western world’s average healthcare costs are far greater in contrast to those in the developing economies. North America alone is in charge of circa a half of the world’s overall spending on healthcare services. With budgets curtailments and growing costs, technology advances are increasingly taking a new meaning in the global Healthcare universe.

The research reports offer comprehensive insights into the market sizing, structure and dynamics of the Healthcare Industry based on various geographies, as well as in-depth market segmentation. The research reports incorporated in this Catalogue closely investigate the competition in the Healthcare Market, besides profiling countless market participants. Moreover, tomorrow's healthcare-related challenges are addressed, as well as projections into the future are provided in the research reports.

Publications found: 71,946

Sort by:

Cyclin Dependent Like Kinase 5 (Serine-Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cyclin Dependent Like Kinase 5 (Serine-Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) Drugs in Development by The...

May 2022 36 pages

Cystine-Glutamate Transporter (Amino Acid Transport System Xc or Calcium Channel Blocker Resistance Protein CCBR1 or Solute Carrier Family 7 Member 11 or xCT or SLC7A11) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cystine-Glutamate Transporter (Amino Acid Transport System Xc or Calcium Channel Blocker Resistance Protein CCBR1 or Solute Carrier Family 7 Member 11 or xCT or SLC7A11) Drugs in Development by Therap...

May 2022 36 pages

Cystinuria Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Cystinuria Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Cystinuria Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides a...

May 2022 38 pages

Cytokine Receptor Common Subunit Gamma (Interleukin 2 Receptor Subunit Gamma or GammaC or p64 or CD132 or IL2RG) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cytokine Receptor Common Subunit Gamma (Interleukin 2 Receptor Subunit Gamma or GammaC or p64 or CD132 or IL2RG) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type...

May 2022 51 pages

Cytokine Release Syndrome (Cytokine Storm) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Cytokine Release Syndrome (Cytokine Storm) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Cytokine Release Syndrome (Cytokine Storm) Drugs in Development by St...

May 2022 48 pages

Cytopenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Cytopenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Cytopenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an...

May 2022 116 pages

Cytosolic Phospholipase A2 (Phospholipase A2 Group IVA or PLA2G4A or EC 3.1.1.4 or EC 3.1.1.5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cytosolic Phospholipase A2 (Phospholipase A2 Group IVA or PLA2G4A or EC 3.1.1.4 or EC 3.1.1.5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SU...

May 2022 41 pages

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players...

May 2022 113 pages

D Amino Acid Oxidase (DAAO or DAMOX or DAO or EC 1.4.3.3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

D Amino Acid Oxidase (DAAO or DAMOX or DAO or EC 1.4.3.3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY D Amino Acid Oxidase (DAAO or D...

May 2022 35 pages

D1A Dopamine Receptor (Dopamine D1 Receptor or DRD1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

D1A Dopamine Receptor (Dopamine D1 Receptor or DRD1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY D1A Dopamine Receptor (Dopamine D1 R...

May 2022 66 pages

D1B Dopamine Receptor (D5 Dopamine Receptor or D1 Beta Dopamine Receptor or Dopamine D5 Receptor or DRD5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

D1B Dopamine Receptor (D5 Dopamine Receptor or D1 Beta Dopamine Receptor or Dopamine D5 Receptor or DRD5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key...

May 2022 45 pages

D2 Dopamine Receptor (Dopamine D2 Receptor or DRD2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 3,500.00

D2 Dopamine Receptor (Dopamine D2 Receptor or DRD2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY D2 Dopamine Receptor (Dopamine D2 Rec...

May 2022 140 pages

D3 Dopamine Receptor (Dopamine D3 Receptor or DRD3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

D3 Dopamine Receptor (Dopamine D3 Receptor or DRD3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY D3 Dopamine Receptor (Dopamine D3 Rec...

May 2022 83 pages

D4 Dopamine Receptor (D2C Dopamine Receptor or Dopamine D4 Receptor or DRD4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

D4 Dopamine Receptor (D2C Dopamine Receptor or Dopamine D4 Receptor or DRD4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY D4 Dopamine...

May 2022 51 pages

Dedifferentiated Liposarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Dedifferentiated Liposarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Dedifferentiated Liposarcoma Drugs in Development by Stages, Target, MoA, RoA, Mole...

May 2022 51 pages

Delayed Graft Function (DGF) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Delayed Graft Function (DGF) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Delayed Graft Function (DGF) Drugs in Development by Stages, Target, MoA, RoA, Mole...

May 2022 39 pages

Delta Type Opioid Receptor (DOR1 or OPRD or OPRD1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Delta Type Opioid Receptor (DOR1 or OPRD or OPRD1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Delta Type Opioid Receptor (DOR1 or OP...

May 2022 87 pages

Dementia Associated With Alzheimers Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Dementia Associated With Alzheimers Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Dementia Associated With Alzheimer's Disease Drugs in Development by...

May 2022 67 pages

Dental Caries Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Dental Caries Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Dental Caries Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players prov...

May 2022 35 pages

Dental Pain (Toothache-Tooth Pain) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Dental Pain (Toothache-Tooth Pain) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Dental Pain (Toothache/Tooth Pain) Drugs in Development by Stages, Target, Mo...

May 2022 38 pages

Dermatological Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Dermatological Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Dermatological Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Typ...

May 2022 61 pages

Diabetic Neuropathic Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Diabetic Neuropathic Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Diabetic Neuropathic Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule T...

May 2022 75 pages

Diastolic Heart Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Diastolic Heart Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Diastolic Heart Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type...

May 2022 61 pages

Dihydrofolate Reductase (DHFR or EC 1.5.1.3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Dihydrofolate Reductase (DHFR or EC 1.5.1.3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Dihydrofolate Reductase (DHFR or EC 1.5.1.3)...

May 2022 47 pages

Dihydroorotate Dehydrogenase (Quinone) Mitochondrial (Dihydroorotate Oxidase or DHODH or EC 1.3.5.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Dihydroorotate Dehydrogenase (Quinone) Mitochondrial (Dihydroorotate Oxidase or DHODH or EC 1.3.5.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Play...

May 2022 50 pages

DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY D...

May 2022 40 pages

DNA Directed RNA Polymerase (POLR2 or EC 2.7.7.6) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

DNA Directed RNA Polymerase (POLR2 or EC 2.7.7.6) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY DNA Directed RNA Polymerase (POLR2 or E...

May 2022 69 pages

DNA Repair Protein RAD51 Homolog 1 (RAD51 Homolog A or RAD51) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

DNA Repair Protein RAD51 Homolog 1 (RAD51 Homolog A or RAD51) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY DNA Repair Protein RAD51 Ho...

May 2022 37 pages

DNA Topoisomerase I (TOP1 or EC 5.99.1.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

DNA Topoisomerase I (TOP1 or EC 5.99.1.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY DNA Topoisomerase I (TOP1 or EC 5.99.1.2) Drugs...

May 2022 97 pages

DNA Topoisomerase II (EC 5.99.1.3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

DNA Topoisomerase II (EC 5.99.1.3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY DNA Topoisomerase II (EC 5.99.1.3) Drugs in Developmen...

May 2022 110 pages

DNA Topoisomerase IV (EC 5.99.1.3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

DNA Topoisomerase IV (EC 5.99.1.3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY DNA Topoisomerase IV (EC 5.99.1.3) Drugs in Developmen...

May 2022 68 pages

Double Homeobox Protein 4 (Double Homeobox Protein 10 or DUX4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Double Homeobox Protein 4 (Double Homeobox Protein 10 or DUX4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Double Homeobox Protein 4...

May 2022 41 pages

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Dr...

May 2022 64 pages

Drug-Induced Dyskinesia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Drug-Induced Dyskinesia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Drug-Induced Dyskinesia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type...

May 2022 55 pages

Drug Toxicity Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Drug Toxicity Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Drug Toxicity Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players prov...

May 2022 298 pages

Dry (Atrophic) Macular Degeneration Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Dry (Atrophic) Macular Degeneration Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Dry (Atrophic) Macular Degeneration Drugs in Development by Stages, Target,...

May 2022 103 pages

Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK-ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK-ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, Ro...

May 2022 55 pages

Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK-ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK-ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, Ro...

May 2022 51 pages

Ductal Carcinoma In Situ Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Ductal Carcinoma In Situ Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Ductal Carcinoma In Situ Drugs in Development by Stages, Target, MoA, RoA, Molecule Typ...

May 2022 36 pages

Duodenal Ulcer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Duodenal Ulcer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Duodenal Ulcer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players pr...

May 2022 42 pages

Dystonia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Dystonia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Dystonia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an ov...

May 2022 43 pages

Ectonucleotide Pyrophosphatase-Phosphodiesterase Family Member 1 (Membrane Component Chromosome 6 Surface Marker 1 or Phosphodiesterase I-Nucleotide Pyrophosphatase 1 or Plasma Cell Membrane Glycoprotein PC1 or ENPP1 or EC 3.1.4.1 or EC 3.6.1.9) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Ectonucleotide Pyrophosphatase-Phosphodiesterase Family Member 1 (Membrane Component Chromosome 6 Surface Marker 1 or Phosphodiesterase I-Nucleotide Pyrophosphatase 1 or Plasma Cell Membrane Glycoprot...

May 2022 40 pages

Edema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Edema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Edema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview...

May 2022 44 pages

Emesis (Vomiting) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Emesis (Vomiting) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Emesis (Vomiting) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Play...

May 2022 48 pages

Emphysema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Emphysema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Emphysema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an...

May 2022 43 pages

Endocarditis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Endocarditis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Endocarditis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provid...

May 2022 35 pages

Endocrine Gland Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Endocrine Gland Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Endocrine Gland Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule T...

May 2022 52 pages

Endothelin 1 Receptor (Endothelin A Receptor or EDNRA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Endothelin 1 Receptor (Endothelin A Receptor or EDNRA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Endothelin 1 Receptor (Endothelin...

May 2022 46 pages

Endothelin B Receptor (Endothelin Receptor Non Selective Type or EDNRB) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Endothelin B Receptor (Endothelin Receptor Non Selective Type or EDNRB) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Endothelin B Rece...

May 2022 42 pages

Endotoxemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Endotoxemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Endotoxemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides...

May 2022 36 pages

Filters

Clear all

Price

—

Date

—

Pages

—

Offers

33% OFF on “TCR-Based Antibody a...

Discount Offer from GMD Research

280

Special Offer from MP Advisors

Special Offer on Therapy Class R...